arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Zai Lab Ltd

ZLAB
$22.59 ▼ -0.24 (-1.05%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zai Lab Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $24.7B
Dividend Yield —
Revenue Growth 15.3% ↘
Op. Margin -49.9% ↗
ROIC -31.5% ↗
FCF / Share $-0.15 ↗
Trailing P/E —
Price / Book 34.9x
FCF Yield —
Debt / Equity 0.29
info Valuation on last close. End-of-day price, Nov 5, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$460.16M
↑ +15.3% —
Net Income Profit after all expenses
$-175.54M
↑ +31.7% —
Operating Margin Operating profit as % of sales
-49.9%
↑ +29.5% 5th
FCF / Share Free cash flow per share
$-0.15
↑ +34.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
6
Returns ↑
26
Financial Health ↑
41
Cash Quality ↑
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 32 quarters